Abstract
BackgroundMycobacterium Tuberculosis (TB) infection is one of the typical adverse events during the treatment with biologics, especially anti-tumour necrosis factor (TNF) agents, in patients with rheumatic disease. The screening of...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
